Clinical Research Enrolling
| Condition | Research Study | Main I/E | Study Type | CT.gov Link | PI | Primary Coordinator | PC Number | Back-Up Coordinator | BC Number |
|---|---|---|---|---|---|---|---|---|---|
| GN - all types | GDCN Registry | Kidney disease, healthy controls, disease controls | Registry, Biobank | NA | Falk | lmccabe@email.unc.edu | 919-445-2635 | ||
| AKI | KPMP AKI Cohort | eGFR >45; creatinine >=1.5 times baseline, evidence of AKI | Observational; Biobank | NCT04334707 | Mottl | anne_froment@med.unc.edu | 919-445-2622 | ||
| ANCA | Pathobiology of ANCA | New or flaring ANCA | Translational | NA | Falk | mmcollie@live.unc.edu | 919-445-2696 | ||
| ANCA | CD5 WATCH (B cell recovery) | 1 month in remission (after 1st treatment or 1st relapse in AAV) | Device | NCT03906227 | Derebail | anne_froment@med.unc.edu | 919-445-2622 | ||
| Anti-GBM | GOOD-IDES-O2 (lmlifidase) | Newly diagnosed (<14 days), Hematuria, eGFR<20 | Phase 3 | NCT05679401 | Derebail | anne_froment@med.unc.edu | 919-445-2622 | ||
| IgAN | ASSIST (Atrasentan) | Biopsy proven IgA; eGFR >=30; Receiving RAS; On or willing to be on SGLT2 inhibitor | Phase 2 | NCT05834738 | Mottl | anne_froment@med.unc.edu | |||
| MN | REBOOT (belimumab and rituximab) | primary MN biopsied in last 3 years; age 18-75; eGFR > 40; proteinuria > 4g/day; BP < 140/90 | Phase 2 | NCT03949855 | Derebail | anne_froment@med.unc.edu | 919-445-2622 | ||
| MN, MCD, FSGS | NEPTUNE ( Nephrotic Syndrome Study Network) | Must be enrolled PRE BIOPSY; UPCR≥1.5 | Observational; Biobank | NCT01209000 | Derebail/Gibson (Peds) | sara_kelley@med.unc.edu | 919-445-2658 | ||
| MN, MCD, FSGS, IgA | CureGN (Cure Glomerulonephropathy Network) | Biopsied in the last 5 years; ancillary study now available for diabetes at biopsy | Observational; Biobank | NA | Mottl | tcamero@email.unc.edu | 919-445-2898 | caroline_poulton@unc.edu | 919-445-2636 |
| PEDS: FSGS, MCD, IGAN, IGAV | EPPIK (Sparsenten) | eGFR ≥30; BP between 5th-95th percentile; UP/C ≥1.0g/g; biopsy proven disease | Phase 2 | NCT05003986 | Gibson | anne_froment@med.unc.edu | 919-445-2622 | ||
| LUPUS | MiSLE - Mesenchymal Stem Cells for refractory lupus | BILAG A or B, Sledai score > 5, completed 6 months induction therapy | Phase 2 | NCT02633163 | Sheikh | julie_walker@med.unc.edu | 919-843-6619 | ||
| LUPUS | VOCAL (Voclosporin) | Ages 12-17, SLE biopsied in last year, evidence of active nephritis | Phase 3 | NCT05288855 | Gibson | anne_froment@med.unc.edu | 919-445-2622 | anne_froment@med.unc.edu | |
| Nephrotic Syndrome | INShore (Obinituzimab) | Ages 2-25; frequently relapsing/steroid dependednt NS diagnosed prior to age 18, UPCR<=0.2g/g, at least 1 relpase in past 6 months | Phase 3 | NCT05627557 | Gibson | anne_froment@med.unc.edu | 919-445-2622 | ||
| DKD | TRIDENT | Diabetes, >= 18yo, getting a biopsy: must be enrolled PRE-BIOPSY | Observational; Biobank | NCT02986984 | Mottl | sara_kelley@med.unc.edu | 919-445-2658 | anne_froment@med.unc.edu | 919-445-2622 |
| DKD | CONFIDENCE | Type 2 diabetes, eGFR 30-75, UACR 300-5000 mg/g | Phase 2 | NCT05254002 | Mottl | sara_kelley@med.unc.edu | 919-445-2658 | anne_froment@med.unc.edu | 919-445-2622 |
| Undergoing CEUS | Contrast Enhanced Ultrasound of the Kidneys Registry | Patients undergoing CEUS | Registry | NA | Chang | anne_froment@med.unc.edu | 919-445-2622 | ||
| CKD | KPMP CKD Cohort | eGFR 30-59; eGFR >=60 if albuminuria/proteinuria present | Observational; Biobank | NCT04334707 | Mottl | anne_froment@med.unc.edu | 919-445-2622 | ||
| CKD | THRiVE (Vascular Access Education) | eGFR <= 20 or Kidney Failure Risk Equation Score >40%; documentation of discussion about dialysis | Interventional | NCT05997875 | Flythe | veronica_joseph@med.unc.edu | 919-966-4615 | ||
| CKD, Non-Diabetic | AMPLITUDE | 18-60 years old, UPCR >0.7g/g - <10g/g, eGFR >25 - <75 | Phase 2/3 | NCT05312879 | Derebail | sara_kelley@med.unc.edu | 919-445-2658 | anne_froment@med.unc.edu | 919-445-2622 |
Contact by phone: Anne Froment 5-2622, Sara Kelley 5-2658, Caroline Poulton 5-2636